Skip to main content
SpringerLink
Log in

Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor

  • Case Report
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Two patients with thalassemia minor and end-stage renal failure on hemodialysis were treated with epoetin zeta (Silapo®, Retacrit®; STADA, Germany), a medicinal product that was developed and registered as biosimilar to epoetin alfa. Dosing was titrated individually for two patients to achieve a stable hemoglobin (Hb) concentration of 10.5–12.0 g/dL. One patient was treated intravenously with epoetin zeta; the other patient was treated subcutaneously. After 12 weeks of therapy both patients achieved Hb levels within the target range, confirming the effi cacy of epoetin zeta in patients with thalassemia minor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Di Iorio BR, Aucella F, Stallone C, Bellizzi V, Thalassaemia Minor in Hemodialysis Study Group. Thalassaemia minor: national survey of uraemic patients under substitutive treatment [in Italian]. G Ital Nefrol. 2002;19:286–293.

    PubMed  Google Scholar 

  2. Cheng IK, Lu HB, Wei DC, Cheng SW, Chang CY, Lee FC. Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. Am J Nephrol. 1993;13:142–148.

    Article  PubMed  CAS  Google Scholar 

  3. Dore F, Bonfigly S, Gaviano E, Pardini S, Longinotti M. Serum transferrin receptor levels in patients with thallassemia intermedia during rHuEPO administration. Haematologica. 1996;81:37–39.

    PubMed  CAS  Google Scholar 

  4. Voulgari PV, Chaidos A, Tzouvara E, et al. Antierythropoietin antibodies in thalassemia patients. Ann Hematol. 2004;83:22–27.

    Article  PubMed  CAS  Google Scholar 

  5. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. SECTION II. Targets for anaemia treatment. Nephrol Dial Transplant. 2004;19(suppl. 2):ii6–ii15.

    Google Scholar 

  6. Tarng DC, Huang TP, Chen TW, Fan CY, Chang JG. Resistance to recombinant human erythropoietin treatment in the thalassaemic patients on chronic haemodialysis: a real clinical entity? Nephrol Dial Transplant. 1996;11:1893–1895.

    PubMed  CAS  Google Scholar 

  7. Kagan A, Sinay-Trieman L, Bar-Khayim Y. Recombinant human erythropoietin for anemia in thalassaemia minor patients on dialysis. Nephrol Dial Transplant. 1995;10:2375–2376.

    PubMed  CAS  Google Scholar 

  8. Cozma G, Cozma MC, Mattes U. Beneficial effect of recombinant human erythropoietin in beta thalassaemia patients on dialysis. Nephrol Dial Transplant. 1992;7:82–83.

    PubMed  CAS  Google Scholar 

  9. Milford D, Winterborn MH. Resistance to recombinant human erythropoietin in a child with renal failure, cystinosis and betathalassaemia minor. Nephron. 1993;64: 645–646.

    Article  PubMed  CAS  Google Scholar 

  10. Lai KN, Wong KC, Li PK, Lui SF. Use of recombinant erythropoietin in thalassemic patients on dialysis. Am J Kidney Dis.1992;19:239–245.

    PubMed  CAS  Google Scholar 

  11. Di Iorio B, Guastaferro P, Gironda A, et al. Can anemia be corrected in haemodialysis patients with thalassaemia minor? [in Italian]. G Ital Nefrol. 2002;19:552–559.

    PubMed  Google Scholar 

  12. Christopoulou V, Varsou A, Travlou A, Drivas G. Erythrocyte ferritin in patients with chronic renal failure and heterozygous beta-thalassemia. Nephron. 2002;91: 463–467.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Multidisciplinary Hospital for Active Treatment “St. George” Ltd., Division of Nephrology and Hemodialysis, Plovdiv, Bulgaria

    E. Kumchev, D. Dimitrakov, P. Stavrev & G. Tsochev

  2. CCDRD AG, Neuenhagen, Germany

    R. Koytchev

  3. STADA R&D GmbH, Bad Vilbel, Germany

    M. Siebert-Weigel

  4. CCDRD AG, Fontanestrasse 84-90, 15366, Neuenhagen, Germany

    R. Koytchev

Authors
  1. E. Kumchev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Koytchev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Dimitrakov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Stavrev
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Tsochev
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Siebert-Weigel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Koytchev.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumchev, E., Koytchev, R., Dimitrakov, D. et al. Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor. Adv Therapy 25, 1375–1378 (2008). https://doi.org/10.1007/s12325-008-0119-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-008-0119-6

Keywords

Search

Navigation